Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?

Autor:	De Francia, Silvia, Berchialla, Paola, Armando, Tiziana, Storto, Silvana, Allegra, Sarah, Sciannameo, Veronica, Soave, Giulia, Sprio, Andrea Elio, Racca, Silvia, Caiaffa, Maria Rosaria, Ciuffreda, Libero, Mussa, Maria Valentina
Předmět:	THERAPEUTIC use of antineoplastic agents BALDNESS NAUSEA MUCOSITIS TASTE disorders PAIN CANCER chemotherapy MULTIPLE regression analysis CONSTIPATION ANTINEOPLASTIC agents RETROSPECTIVE studies MANN Whitney U Test FISHER exact test SURGICAL complications COLORECTAL cancer SEX distribution RISK assessment CANCER patients VOMITING DESCRIPTIVE statistics HEARTBURN THROMBOCYTOPENIA DRUG toxicity
Zdroj:	European Journal of Clinical Pharmacology; Jun2022, Vol. 78 Issue 6, p1029-1038, 10p, 4 Charts
Abstrakt:	Purpose: Given the biological differences between females and males, sex-specific evaluations should be carried out to obtain better cancer prevention, diagnosis, and treatment strategies. To this purpose, our aim was to evaluate sex differences for toxicity in a cohort of colorectal cancer (CRC) patients undergoing chemotherapy. Methods: We performed a retrospective study in 329 CRC patients. Differences between males and females were tested performing the Mann-Whitney U test or the Fisher exact test. Multivariate logistic regression models were computed to evaluate the association between sex and risk of chemotherapy agent-related toxicity. Results: According association sex toxicity, significant differences were observed in the median number of episodes of nausea (p = 0.044), vomit (p = 0.007), heartburn (p = 0.022), thrombocytopenia (p = 0.005), mucositis (p = 0.024). Moreover, statistically significant differences between males and females were observed in the distribution of the highest toxicity grades of nausea (p = 0.024), heartburn (p = 0.016), and thrombocytopenia (p = 0.034). Females have an increased risk of vomit (p = 0.002), alopecia (p = 0.035), heartburn (p = 0.005), mucositis (p = 0.003), and lower risk for thrombocytopenia (p = 0.005). Conclusion: According to the association of sex chemotherapy agent-related toxicities, females resulted on average at a significant increased risk of more common adverse events (constipation, dysgeusia, alopecia, heartburn, vomit, asthenia, nausea, pain events, and mucositis). Sex-tailored CRC chemotherapy treatment is necessary to obtain efficacy avoiding toxicity, based on patients' biological and genetic characteristics, a vision that would change CRC setting, a stable disease but still orphan of a real tailored approach. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Full text from SpringerLink